Iradimed Posts Record Q3 Revenue, Eyes $100M Run Rate
As seen on the 24/7 Wall St. homepage on October 30, 2026.
Management now guides Q4 to $25.0 million to $26.5 million, a $100 million annualized run rate, after record revenue broke a two-quarter slide. Over 70% of pump bookings were quad-stack units that double infusion capacity per MRI suite, with EPS meeting expectations.
Continue ReadingShow less
Iradimed reported Q3 2026 revenue of $24.2 million, up 14.2% year over year and beating expectations, snapping a two-quarter revenue slide and setting a new quarterly record.
The driver was the commercial ramp of the 3870 MRI-compatible IV infusion pump, with domestic pump bookings up 45% year over year.
Gross margin came in at 76%, below the 78% recorded a year ago, as the company works through the production ramp on the 3870.
Sponsored
Management guided Q4 2026 revenue to $25.0 million to $26.5 million, a range the company says represents a $100 million annualized run rate.
The company declared a quarterly cash dividend of $0.20 per share, payable November 27 to shareholders of record as of November 13.
Mentioned: IRMD